Comparing the effectiveness of two glaucoma treatments

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the efficacy of Simbrinza and Rocklatan compared to Cosopt and Latanoprost in adults diagnosed with mild to moderate open-angle glaucoma. It is a randomized, multi-site, parallel-group, prospective study involving patients who have been using the combination of Cosopt and Latanoprost for at least one month. The study aims to assess the impact of these treatments on optic nerve damage as defined by established ophthalmological guidelines.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Adults aged Eighteen (18) years and older with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month. Evidence of optic nerve damage will be based on AAO Preferred Practice Patterns guidelines using either or both of the following:
* Optic disc or retinal nerve fiber layer (RNFL) structural abnormalities
* Diffuse or focal narrowing, or notching, of the optic disc rim, especially at the inferior or superior poles, which forms the basis for the ISNT rule
* Progressive narrowing of the neuroretinal rim with an associated increase in cupping of the optic disc
* Diffuse or localized abnormalities of the parapapillary RNFL, especially at the inferior or superior poles
* Disc rim, parapapillary RNFL, or lamina cribrosa hemorrhages
* Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue
* Large extent of parapapillary atrophy
* Reliable and reproducible visual field abnormality considered a valid representation of the subject's functional status
* Visual field damage consistent with RNFL damage (e.g. nasal step, arcuate field defect, or paracentral depression in clusters of test sites)
* Visual field loss across the horizontal midline in one hemifield that exceeds loss in the opposite hemifield (in early/ moderate cases)
* Absence of other known explanations (e.g. optic disc drusen, optic nerve pit)
* Mean diurnal IOP ≥ 18 mmHg and \< 28 mmHg at baseline in at least one eye with an inter-eye IOP difference \< 5 mmHg.
* A central corneal thickness (CCT) within the range of 450-650 µm

Exclusion criteria:

* Patients with prior ocular procedures or intraocular surgery within 1 year prior to baseline (e.g. cataract surgery).
* Patients with prior history of glaucoma surgeries or laser treatment except patients with history of SLT \>1 yr prior to baseline.
* Contraindications or known hypersensitivity to any or all the study medications including Rocklatan, Simbrinza, Cosopt and Latanoprost or related class of drugs.
* Patients with known history or presence of uncontrolled systemic diseases including diseases that, in investigator's opinion, may make it unsafe or undesirable for the subject to participate in the study and/ or limit adherence.
* Patients with known history or presence of significant ocular diseases including corneal diseases, dystrophies or abnormalities that would prevent accurate IOP readings with GAT.
* Patients with a history of uncontrolled IOP with the combination of either Rocklatan + Simbrinza or Cosopt + Latanoprost dual therapy.
* Significant ocular surface findings (e.g. hyperemia, irritation) found during slit lamp examination that might affect the study.
* Chronic use of any systemic medication for chronic diseases that may affect IOP.
* Subjects who are pregnant, lactating or planning a pregnancy.
* Any condition in the opinion in the investigator that would potentially confound the results of this study

Where it's running

• Prairie Eye Center
  Springfield, Illinois, United States Recruiting

Study contacts

• Principal investigator: Sandra Yeh, MD — Prairie Eye Center
• Study coordinator: Jennifer Lyons
• Email: jenniferlyons37@gmail.com
• Phone: 217-257-3102

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rocklatan versus latanoprost for 24-hour eye pressure control in open-angle glaucoma and ocular hypertension

  This trial tests whether a combination eye drop (Rocklatan) lowers eye pressure over 24 hours more than latanoprost alone in adults with open-angle glaucoma or ocular hypertension.

  Recruiting Phase 4 Mayo Clinic · Rochester, Minnesota · NCT07325240

• Patient quality of life after different glaucoma surgeries

  This project uses the NEI-VFQ-25 vision questionnaire to see if adults who have PreserFlo MicroShunt, trabeculectomy, or non-penetrating deep sclerectomy report different quality of life after surgery.

  Recruiting Hospices Civils de Lyon · Lyon · NCT07303257

• iStent infinite plus iDose TR for moderate-to-severe open-angle glaucoma

  This trial will see if placing an iStent infinite device together with an iDose TR travoprost implant can lower eye pressure and reduce glaucoma eye drops for people with moderate to severe open-angle glaucoma not controlled by medication or laser.

  Recruiting Phase 4 Wills Eye · Philadelphia, Pennsylvania · NCT07228221

• Eye-surface inflammation after replacing nightly preserved glaucoma drops with a Durysta implant

  We will try a single Durysta intracameral implant to see if cutting back nightly preserved glaucoma drops reduces eye-surface inflammation in people with open-angle glaucoma or ocular hypertension who are pseudophakic and have signs of surface damage.

  Recruiting Phase 4 University of Miami · Miami, Florida · NCT07217678

• Evaluating the effectiveness of surgical systems for treating open-angle glaucoma

  This study looks at how well a combination of surgical treatments can lower eye pressure in people with open-angle glaucoma over three years.

  Recruiting Barnet Dulaney Perkins Eye Centers · Mesa, Arizona · NCT06953349

• Vitamin mix for glaucoma patients

  This study is testing if a mix of certain vitamins can help protect the eyes and slow vision loss in people with glaucoma.

  Recruiting Karolinska Institutet · Stockholm, Stockholm County and 1 other locations · NCT06885827

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.